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Introduction 1 
Acute kidney injury (AKI) is defined as any rapid loss of kidney function. It is 2 
characterised by the retention of nitrogenous (urea and creatinine) and non-3 
nitrogenous waste products, and disordered regulation of fluid, electrolytes 4 
and acid-base balance. The term AKI covers a spectrum from minor changes 5 
in urine output and blood results to kidney failure requiring renal replacement 6 
therapy. Evidence suggests that even relatively small changes in kidney 7 
function may be associated with poor patient outcomes,1 thus AKI has 8 
replaced the older and narrower concept of “acute renal failure” in clinical 9 
practice. 10 
 11 
Updated definitions and diagnostic criteria for AKI achieved widespread usage 12 
concurrently with an increased focus on AKI by healthcare institutions. In 13 
2009 NCEPOD published “Acute Kidney Injury: Adding Insult to Injury”.2 This 14 
report recognised that AKI is a common problem often caused by systemic 15 
deficiencies in care and giving rise to significant healthcare costs. Following 16 
the publication of the NCEPOD report, the National Institute of Health and 17 
Care Excellence (NICE) developed a guideline (CG169) for the prevention, 18 
detection and management of AKI which was first published in August 2013.3 19 
More recently, a UK-wide programme supported both by the NHS and 20 
independent funding bodies, “Think Kidneys”, has sought to raise awareness 21 
of kidney health with separate strands focusing on both AKI and Chronic 22 
Kidney Disease (CKD). 23 
 24 
AKI is a syndrome with numerous causes that may complicate many co-25 
existent illnesses. Syndrome focused management may help improve delivery 26 
of care for people with multimorbidity and shift focus away from guidance 27 
focused on single diseases towards improved generalist care.4 28 
 29 
Approximately 15-20% of patients admitted to hospital may have AKI5 and 30 
community acquired AKI may both affect younger patients and be more 31 
severe.6 As a result, AKI may have the potential to act as a barometer of 32 
safety in patient care delivered across the interfaces between primary and 33 
secondary care. 34 
 3 
 1 
Recognising Risk and Making The Diagnosis 2 
AKI frequently complicates acute illnesses such as sepsis and conditions that 3 
result in hypovolaemia. The co-existence of common medical problems with 4 
acute illness may increase the risk of patients acquiring AKI (Box 1). Patients 5 
presenting with acute illness and any of the risk factors listed in Box 1 should 6 
be assessed for AKI. In secondary care, this assessment is by measurement 7 
of serum creatinine and comparison to baseline. However, in primary care, 8 
the requirement for blood tests will be dictated by clinical circumstances. For 9 
example, where there is evidence of sepsis, urgent transfer to an emergency 10 
department is the priority. Alternatively, measurement of serum creatinine 11 
may not be required for patients with an apparent self-limiting acute illness. 12 
Between these two extremes, priority of serum creatinine testing should be 13 
given to those patients with the co-existing illnesses seen in Box 1. 14 
 15 
The current diagnostic criteria for AKI are shown in Box 2. As can be seen, 16 
diagnosis of AKI is based on an increase in a patient’s serum creatinine 17 
and/or fall in urine output. These diagnostic criteria do not include estimated 18 
glomerular filtration rate (eGFR), which is calculated from one of various 19 
available formulae that all utilise serum creatinine measurements. This is 20 
notably different from the current approach to the diagnosis and staging of 21 
CKD in the UK, which is based on eGFR values.7 Equations used to calculate 22 
eGFR were originally derived from patients with CKD without acute illnesses 23 
and therefore do not take into account the rapid changes in serum creatinine 24 
seen in patients with AKI. 25 
 26 
The diagnosis and severity staging of AKI (See Table 1) requires comparison 27 
with a baseline serum creatinine reading. There is no standard definition of 28 
baseline creatinine, but for each patient this is regarded as the stable 29 
creatinine value before they had AKI. Calculated values of baseline creatinine 30 
are of little use in the diagnosis of AKI.8 As a result, it is crucial for clinicians to 31 
seek out and use true baseline creatinine measurements. Sometimes this 32 
requires going back through notes or electronic records to establish the last 33 
lowest and stable value. Where previous measurements of creatinine are not 34 
 4 
available, admission serum creatinine should be used as a baseline in 1 
patients admitted to hospital.  2 
 3 
In 2014 NHS England issued a patient safety alert recommending 4 
standardisation of the early identification of AKI using a national algorithm 5 
based on the staging system in Table 1. The alert also promoted the 6 
development and adoption of electronic alerts for AKI in both primary and 7 
secondary care. Whilst the use of these systems is of significant potential use, 8 
the gold standard for diagnosis of AKI remains “clinician review of current and 9 
previous blood results – taking clinical context into account – and comparing 10 
against AKI diagnostic and staging criteria”.9 Maximizing utility of these 11 
electronic alerts in primary care whilst minimizing potential burden remains on 12 
area of active research but “Think Kidneys” have produced guidance for 13 
recommended response times to AKI alerts.9 14 
 15 
Finding the Cause 16 
Where possible the cause of AKI should be promptly determined. It is 17 
estimated that approximately 70% of cases of AKI involve sepsis and 18 
hypotension10 and therefore many causes of AKI can be elucidated on 19 
standard clinical assessment. Medicines are also common causes of AKI, and 20 
detection or suspicion of AKI should prompt a full review of all prescribed, 21 
over the counter, herbal or complimentary medicines, and ‘recreational’ 22 
substances for each patient. Up to 10% of AKI may be due to obstruction.11 23 
Therefore, symptoms of lower urinary tract obstruction or renal colic should be 24 
asked about specifically to guide further investigation.  25 
 26 
Where no clear acute illness is present but AKI is diagnosed, it is important to 27 
consider less common causes such as myeloma or systemic vasculitis. The 28 
“3Hs and 3Rs” (haemoptysis, haemolysis, hypercalcaemia, rash, recent 29 
vascular intervention, raised creatine kinase)12 are a useful screening tool for 30 
uncommon causes of AKI and the presence of any of these with a raised 31 
creatinine should prompt referral to secondary care (see Table 2). 32 
 33 
 5 
Dipstick urinalysis for blood, protein, leucocytes, nitrites and glucose is a 1 
mandatory investigation in AKI. The presence of dipstick abnormalities is 2 
often sensitive but not necessarily specific, and AKI often occurs with a 3 
normal dipstick analysis. Patients with urinary catheters or a urological history 4 
(e.g. ureteric stents or chronic cystitis) may have chronically abnormal dipstick 5 
results. On the other hand, patients with volume depletion alone will often 6 
have a normal dipstick. Large amounts of blood and protein (2+ or greater) on 7 
dipstick without another obvious cause for AKI should raise the possibility of a 8 
diagnosis of glomerulonephritis, and necessitate urgent referral to nephrology 9 
services. 10 
 11 
Additional diagnostic testing may include urinary tract ultrasonography. It may 12 
not be necessary to obtain an ultrasound if the cause of AKI is obvious i.e. 13 
profound volume depletion. However, if symptoms and assessment suggest 14 
an obstructed and infected kidney in the presence of AKI (e.g. known stone 15 
disease, fevers, loin pain, solitary kidney) then ultrasound scanning should be 16 
performed within 6 hours.3 Where no obvious cause is found for AKI then 17 
ultrasound scanning should be performed within 24 hours. Ultrasonography is 18 
particularly important in patients who do not present with an acute illness or 19 
AKI risk factors (Box 1), as these patients may have urological obstruction. 20 
Asking about new or worsening urological symptoms may suggest this as a 21 
cause for AKI. 22 
 23 
Management of acute kidney injury 24 
Many different causes of AKI exist, so management will vary from patient to 25 
patient. For example, where urinary retention is present, or ultrasound 26 
scanning reveals upper urinary tract obstruction (i.e. hydronephrosis), the 27 
focus of management will be urological relief of obstruction.  28 
 29 
Some patients will develop stage 3 AKI (see Table 1) and require renal 30 
replacement therapy (RRT). Indications for RRT include hyperkalaemia, 31 
metabolic acidosis, fluid overload, pulmonary oedema, and symptoms of 32 
uraemia (e.g. encephalopathy). Patients with these complications of AKI, 33 
regardless of the cause, should be immediately discussed with nephrology or 34 
 6 
critical care3 to ensure rapid transfer of care to the correct specialists during 1 
their emergency hospital admission (see Table 2). 2 
 3 
The Importance of Medicines Optimisation 4 
In all cases of AKI, knowing what to do with medications is a key part of initial 5 
patient management. If a patient with AKI is taking medication that may impair 6 
kidney function then these medicines should be withheld. The key medicines 7 
to consider withholding are: 8 
 9 
 ACE inhibitors 10 
 Angiotensin Receptor Blockers (ARBs) 11 
 Diuretics  12 
 NSAIDs 13 
 14 
In addition, some medicines e.g. metformin, sulfonylureas, antibiotics and 15 
opiates, may accumulate in AKI and lead to harmful side effects. In the 16 
majority of cases of stage 2 or 3 AKI all of these medicines should be 17 
suspended. 18 
  19 
The “Think Kidneys” programme has recently published guidance on “sick day 20 
rules” for patients at risk of AKI. The anti-hypertensives and oral 21 
hypoglycaemic medicines listed above are commonly prescribed to patients 22 
with diabetes, CKD, and heart failure, which all increase the risk of AKI (see 23 
Box 1). Furthermore, patients with CKD and diabetes may be treated to a 24 
more aggressive blood pressure target of <130/80mmHg7 thus increasing the 25 
risk of hypoperfusion of the kidneys and subsequent AKI. “Sick day rules” 26 
suggest that patients should temporarily discontinue drugs such as NSAIDs, 27 
ACE inhibitors, ARBs, diuretics, metformin, sulfonylureas and trimethoprim 28 
during periods of acute illness such as vomiting, diarrhoea, fevers or sweats. 29 
 30 
The appropriateness of using “sick day rules” in all patients on relevant 31 
medicines remains a topic of debate and the “Think Kidneys” programme 32 
have acknowledged that the evidence for reduction of harm in association 33 
 7 
with this initiative is “very weak”.13 As a result, where patients are deemed to 1 
be at high risk for AKI, the key may be to focus counselling both on cessation 2 
when unwell but also restarting medicines when well in order to avoid 3 
suboptimal treatment of medical conditions after an acute illness.  4 
 5 
One final consideration for optimisation of medicines is that the antibiotic 6 
trimethoprim and the H2 blockers ranitidine and cimetidine, reduce creatinine 7 
secretion into the tubules of the kidney and may increase the serum creatinine 8 
without truly reducing kidney function. This may confuse interpretation of 9 
serum creatinine measurements and lead to false positive diagnoses of AKI. 10 
A clue is often that the plasma urea concentration is relatively unchanged, 11 
compared to the creatinine.  12 
 13 
The “Think Kidneys” programme has produced a document advising on the 14 
use of numerous common medicines in patients with AKI.14 15 
  16 
Referral and Follow Up 17 
Many patients with AKI may be appropriate for referral to hospital acute 18 
services such as ED or acute medicine for assessment and management of 19 
coexistent and causative acute illnesses such as sepsis.  20 
 21 
NICE guideline CG169 contains recommendations for when a specific referral 22 
to nephrology is appropriate in AKI. Clearly where indications for RRT are 23 
met, this requires immediate referral to nephrology or critical care services. 24 
CG169 suggests referral to or discussion with a nephrologist within 24 hours 25 
in a number of situations and these are summarised in Table 2. Local 26 
arrangements to meet this 24-hour recommendation will vary by region and 27 
may include telephone and email advice, dedicated ”hot” clinics or pre-28 
specified arrangements that use general acute medicine services. 29 
 30 
When AKI has resolved it is important to ensure appropriate follow-up and 31 
patient education. Some responsibilities, such as discussion of the risk of 32 
recurrent AKI, and the potential causative role of dehydrating illnesses and 33 
 8 
nephrotoxic drugs such as NSAIDs, will be shared by primary and secondary 1 
care.   2 
 3 
Medicines that may have been discontinued during AKI may need to be 4 
restarted when stability of renal function is attained. If stability is attained 5 
during hospital admission this can be addressed in secondary care, otherwise 6 
secondary care physicians will need to provide discharge advice to facilitate 7 
restarting medicines in primary care. If ACE inhibitors and ARBs are restarted 8 
in the community, monitoring of renal function 2 weeks after restarting is 9 
mandatory. Kidney function may stabilise at a higher creatinine than 10 
previously, thus requiring re-assessment of baseline creatinine and eGFR. 11 
This may be particularly relevant to the use of metformin.15 12 
 13 
Monitoring of kidney function after an episode of AKI will depend on the 14 
underlying cause. In the absence of a specialist diagnosis such as 15 
glomerulonephritis, monitoring should be carried out as per NICE guidance on 16 
CKD.7 Briefly, patients with an eGFR >45ml/min/1.73m2 can be reviewed at 17 
least annually, apart from where they have significant proteinuria. Patients 18 
with an eGFR of between 30 and 44ml/min/1.73m2 should be reviewed twice 19 
yearly or more and patients with an eGFR of beneath 30ml/min/1.73m2 20 
considered for outpatient referral to a nephrologist. 21 
 22 
More generally, data indicates that following an episode of AKI, patients may 23 
be at increased risk of mortality, development or progression of CKD and 24 
readmission to hospital,6 suggesting that an episode of AKI may imply 25 
vulnerability and patient care may need to be individualized to address this. 26 
 27 
Conclusion 28 
AKI is common in both the community and in hospital, and is associated with 29 
high morbidity, mortality, and healthcare costs. Early recognition and potential 30 
prevention of AKI may be associated with improved patient outcomes. 31 
Patients who are at high risk of AKI should be educated about action they can 32 
take themselves to detect and reduce the severity of future AKI episodes. 33 
Whilst the spectrum of disease described by the term AKI is broad, increased 34 
 9 
understanding of its association with acute illness, and the patient benefits 1 
associated with optimisation of relevant medicines, has the potential to 2 
transform management of this condition and remove the “insult from the 3 
injury”.4 
 10 
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Box 1. Conditions that may increase the risk of AKI in the presence of acute 
illness. Adapted from recommendation 1.1.1 of NICE CG169 
Pre-existing Chronic Kidney Disease 
Heart Failure 
Liver Disease 
Diabetes 
History of AKI 
Oliguria 
Neurological or cognitive impairment that may limit access to fluids 
Hypovolaemia 
Use of medicines which impair kidney function 
Use on iodinated contrast within the past week  
Urological obstruction 
Sepsis 
Age over 65 years 
 
Box 2. The Definition of Acute Kidney Injury. Adapted from KDIGO Clinical 
Practice Guideline for Acute Kidney Injury, 2012 
AKI is defined as any of the following: 
 Increase in serum creatinine by 26.5mol/l within 48 hours; or 
 Increase in serum creatinine to 1.5 times baseline, which is 
known or presumed to have occurred within the prior 7 days; or 
 Urine volume <0.5ml/kg/h for 6 hours 
 
  
 13 
Table 1. Staging of AKI 
Stage Serum Creatinine Urine Output 
1 1.5-1.9 times baseline 
OR 
26.5 mol/l increase 
<0.5ml/kg/h for 6-12 
hours 
2 2.0-2.9 times baseline <0.5ml/kg/h for 12 
hours 
3 3.0 times baseline 
OR 
Increase in serum 
creatinine to 353.6mol/l 
OR 
Initiation of renal 
replacement therapy 
<0.3ml/kg/h for 24 
hours 
OR 
Anuria for 12 hours 
 
  
 14 
Table 2. Referring to Nephrology when AKI is present. Adapted from section 
1.5 NICE CG169 
Immediate referral  
 If meet criteria for renal replacement therapy 
Referral within 24 hours 
 A possible diagnosis that may need specialist treatment (e.g. myeloma, 
vasculitis) 
 AKI of unclear cause 
 Inadequate response to treatment 
 Complications associated with AKI 
 Stage 3 AKI 
 A kidney transplant  
 Pre-existing stage 4 or 5 CKD 
Consider referral 
 Where patients have severe illness that might benefit from treatment, 
but there is uncertainty as to whether they are nearing the end of their 
life 
Do not refer 
 Patients who have a clear cause for acute kidney injury and are 
demonstrating a rapid response to medical management, unless they 
have a kidney transplant. 
 
